Aldoxorubicin for metastatic, locally advanced or unresectable soft tissue sarcoma – second line
NIHR HSRIC
Record ID 32016000825
English
Authors' recommendations:
Soft tissue sarcomas are a group of rare cancers that affect tissues that connect, support and surround other body structures and organs. Soft tissue sarcoma can affect any part of the body including the arms, legs and torso. Soft tissue sarcoma can develop in fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
Aldoxorubicin is a new chemotherapy drug given in a drip directly into a vein. Aldoxorubicin is changed into the existing chemotherapy drug doxorubicin inside tumours, and may be useful in treating soft tissue sarcoma where previous treatment has failed.
If licensed for use in the UK, aldoxorubicin will be a new treatment for people with soft tissue sarcoma.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/aldoxorubicin-for-metastatic-locally-advanced-or-unresectable-soft-tissue-sarcoma-second-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Doxorubicin
- Hydrazones
- Sarcoma
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.